^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Oral Cancer |
| Drug: | saracatinib (AZD0530) (Src kinase inhibitor, FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy
Published date:
11/29/2021
Excerpt:
To assess the efficacy of EGFR-targeted therapies in EGFR-amplified OSCC, we generated two patient tumor-derived primary cell lines (PDCLs), one harboring EGFR-amplification (TKCC-OSCC-16) and one without EGFR-amplification (TKCC-OSCC-22)...saracatinib produced IC50 values of 0.32µM for TKCC-OSCC-16 and 6.34µM for TKCC-OSCC-22 (Figure 6E), indicating the TKCC-OSCC-22 cell line was highly resistant to saracatinib...these data demonstrate that the EGFR-amplified TKCC-OSCC-16 cell line was sensitive to all six EGFR inhibitors....The EGFR-amplified TKCC-OSCC-16 cell line displayed approximately 10-fold increased sensitivity to all inhibitors compared to the TKCC-OSCC-22 cells (Figure 6D)...
DOI:
10.3389/fonc.2021.750852
